dc.contributor.author |
Koskinen, Juha M. |
|
dc.contributor.author |
Antikainen, Petri |
|
dc.contributor.author |
Hotakainen, Kristina |
|
dc.contributor.author |
Haveri, Anu |
|
dc.contributor.author |
Ikonen, Niina |
|
dc.contributor.author |
Savolainen-Kopra, Carita |
|
dc.contributor.author |
Sundström, Kati |
|
dc.contributor.author |
Koskinen, Janne O. |
|
dc.date.accessioned |
2021-10-28T07:33:01Z |
|
dc.date.available |
2021-10-28T07:33:01Z |
|
dc.date.issued |
2021-10-13 |
|
dc.identifier.citation |
Koskinen , J M , Antikainen , P , Hotakainen , K , Haveri , A , Ikonen , N , Savolainen-Kopra , C , Sundström , K & Koskinen , J O 2021 , ' Clinical validation of automated and rapid mariPOC SARS-CoV-2 antigen test ' , Scientific Reports , vol. 11 , no. 1 , 20363 . https://doi.org/10.1038/s41598-021-99886-6 |
|
dc.identifier.other |
PURE: 169850130 |
|
dc.identifier.other |
PURE UUID: ebb2f54a-48c8-4272-b1c9-de3f73c68249 |
|
dc.identifier.other |
Scopus: 85117384155 |
|
dc.identifier.other |
WOS: 000707032500004 |
|
dc.identifier.uri |
http://hdl.handle.net/10138/335774 |
|
dc.description |
Publisher Copyright: © 2021, The Author(s). |
|
dc.description.abstract |
COVID-19 diagnostics was quickly ramped up worldwide early 2020 based on the detection of viral RNA. However, based on the scientific knowledge for pre-existing coronaviruses, it was expected that the SARS-CoV-2 RNA will be detected from symptomatic and at significant rates also from asymptomatic individuals due to persistence of non-infectious RNA. To increase the efficacy of diagnostics, surveillance, screening and pandemic control, rapid methods, such as antigen tests, are needed for decentralized testing and to assess infectiousness. A novel automated mariPOC SARS-CoV-2 test was developed for the detection of conserved structural viral nucleocapsid proteins. The test utilizes sophisticated optical laser technology for two-photon excitation and individual detection of immunoassay solid-phase particles. We validated the new method against qRT-PCR. Sensitivity of the test was 100.0% (13/13) directly from nasopharyngeal swab specimens and 84.4% (38/45) from swab specimens in undefined transport mediums. Specificity of the test was 100.0% (201/201). The test's limit of detection was 2.7 TCID50/test. It showed no cross-reactions. Our study shows that the new test can detect infectious individuals already in 20 min with clinical sensitivity close to qRT-PCR. The mariPOC is a versatile platform for syndromic testing and for high capacity infection control screening of infectious individuals. |
en |
dc.format.extent |
10 |
|
dc.language.iso |
eng |
|
dc.relation.ispartof |
Scientific Reports |
|
dc.rights |
cc_by |
|
dc.rights.uri |
info:eu-repo/semantics/openAccess |
|
dc.subject |
3111 Biomedicine |
|
dc.subject |
HUMAN CORONAVIRUS |
|
dc.subject |
PCR |
|
dc.subject |
VIRUSES |
|
dc.subject |
ASSAYS |
|
dc.title |
Clinical validation of automated and rapid mariPOC SARS-CoV-2 antigen test |
en |
dc.type |
Article |
|
dc.contributor.organization |
Department of Clinical Chemistry and Hematology |
|
dc.contributor.organization |
Clinicum |
|
dc.contributor.organization |
Päivi Hotakainen / Principal Investigator |
|
dc.description.reviewstatus |
Peer reviewed |
|
dc.relation.doi |
https://doi.org/10.1038/s41598-021-99886-6 |
|
dc.relation.issn |
2045-2322 |
|
dc.rights.accesslevel |
openAccess |
|
dc.type.version |
publishedVersion |
|